Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces that dosing has commenced with its inhaled interferon beta product in...